Deepak Acharya

Deepak Acharya

Auto-generated profile, based on publicly available information

Deepak Acharya

Division of Cardiology, University of Arizona

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
RLRenzo Y. Loyaga-Rendon
Renzo Y. Loyaga-Rendon
TKToshinobu Kazui
Toshinobu Kazui
DADeepak Acharya
Deepak Acharya
Left ventricular assist devices (LVAD) have revolutionized the management of advanced heart failure. However, complications rates remain high, among which hemorrhagic and thrombotic complications are the most important. Antiplatelet and anticoagulation strategies form a cornerstone of LVAD management and may directly affect LVAD complications. Concurrently, LVAD complications influence anticoagulation and anticoagulation management. A thorough understanding of device, patient, and management, including anticoagulation and antiplatelet therapies, are important in optimizing LVAD outcomes. This article provides a comprehensive state of the art review of issues related to antiplatelet and anticoagulation management in LVADs. We start with a historical overview, the epidemiology and pathophysiology of bleeding and thrombotic complications in LVADs. We then discuss platelet and anticoagulation biology followed by considerations prior to, during, and after LVAD implantation. This is followed by discussion of anticoagulation and the management of thrombotic and hemorrhagic complications. Specific problems, including management of heparin-induced thrombocytopenia, anticoagulant reversal, novel oral anticoagulants, artificial heart valves, and noncardiac surgeries are covered in detail.

1 July 2019 in Pulmonary Circulation
Verified
Journal Article
Open access
PDF file
AEAshraf El‐Dabh
Ashraf El‐Dabh
DADeepak Acharya
Deepak Acharya
Dasatinib and other tyrosine kinase inhibitors are commonly utilized in the management of chronic myelogenous leukemia. Pulmonary hypertension is an important adverse event associated with dasatinib. Mechanisms for pulmonary hypertension include pulmonary endothelial injury, apoptosis, and increased susceptibility to other triggers for pulmonary hypertension. The diagnosis is suspected based on symptoms, suggested by echocardiographic findings, and confirmed with right heart catheterization. Management includes discontinuation of dasatinib and initiation of pulmonary vasodilators. Persistent pulmonary hypertension is present in up to one third of patients after cessation of dasatinib. Other tyrosine kinase inhibitors, including bosutinib, lapatinib, and ponatinib have also been implicated in pulmonary hypertension in small series, although evidence for causation is less robust. A high index of suspicion, continued vigilance for pulmonary hypertension with long‐term use, and early therapy are important in optimizing outcomes in this population.

23 February 2023 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
DADeepak Acharya
Deepak Acharya
TKToshinobu Kazui
Toshinobu Kazui
DRDina Al Rameni
Dina Al Rameni
TATushar Acharya
Tushar Acharya
EBEdward Betterton
Edward Betterton
ACArka Chatterjee
Arka Chatterjee
Aortic valve disorders are important considerations in advanced heart failure patients being evaluated for left ventricular assist devices (LVAD) and those on LVAD support. Aortic insufficiency (AI) can be present prior to LVAD implantation or developde novoduring LVAD support. It is usually a progressive disorder and can lead to impaired LVAD effectiveness and heart failure symptoms. Severe AI is associated with worsening hemodynamics, increased hospitalizations, and decreased survival in LVAD patients. Diagnosis is made with echocardiographic, device assessment, and/or catheterization studies. Standard echocardiographic criteria for AI are insufficient for accurate diagnosis of AI severity. Management of pre-existing AI includes aortic repair or replacement at the time of LVAD implant. Management ofde novoAI on LVAD support is challenging with increased risks of repeat surgical intervention, and percutaneous techniques including transcatheter aortic valve replacement are assuming greater importance. In this manuscript, we provide a comprehensive approach to contemporary diagnosis and management of aortic valve disorders in the setting of LVAD therapy.

27 August 2023 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
CKCatherine E. Kelty
Catherine E. Kelty
MDMichael G. Dickinson
Michael G. Dickinson
MLMarzia Leacche
Marzia Leacche
MJMilena Jani
Milena Jani
NSNabin K. Shrestha
Nabin K. Shrestha
RLRenzo Y. Loyaga-Rendon
Renzo Y. Loyaga-Rendon

24 October 2021 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
MJMilena Jani
Milena Jani
SLSangjin Lee
Sangjin Lee
DADeepak Acharya
Deepak Acharya
SHSarah Hoeksema
Sarah Hoeksema
TBTheodore Boeve
Theodore Boeve
RLRenzo Y. Loyaga‐Rendon
Renzo Y. Loyaga‐Rendon

1 September 2021 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
DADeepak Acharya
Deepak Acharya
RLRenzo Y. Loyaga-Rendon
Renzo Y. Loyaga-Rendon
ACArka Chatterjee
Arka Chatterjee
IRIndranee Rajapreyar
Indranee Rajapreyar
KLKwan Lee
Kwan Lee
Cardiac allograft vasculopathy (CAV) is a challenging complication of heart transplantation. CAV pathophysiology is incompletely understood, standard screening modalities such as angiography have significant limitations, and currently available therapies have only modest efficacy in preventing progression. Optical coherence tomography is a light-based technique that provides microscopic level catheter-based intravascular imaging and has dramatically expanded our understanding of CAV, demonstrating it to be a complex, heterogeneous, and dynamic process. This review covers characteristics and uses of optical coherence tomography, including vessel characterization, serial use to assess progression of disease, guiding percutaneous intervention, and monitoring response to CAV therapies. We also discuss the potential of optical coherence tomography in providing individualized assessment and enable customized CAV therapies, which may lead to improvements in long-term transplant outcomes.